---
schema_version: "secwatch.filing_event.v1"
accession: "0001384101-21-000173"
form_type: "8-K"
ticker: "VCYT"
cik: "0001384101"
company_name: "VERACYTE, INC."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:34:10.090619+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Veracyte Q3 2021 revenue $60.4M (+94% YoY); raises FY guidance to $210-218M

## Summary
- Total revenue $60.4M, up 94% YoY; volume 20,972 tests (+79%).
- Net loss $14.1M ($0.20 EPS) vs $4.1M loss Q3 2020; includes HalioDx costs.
- Completed HalioDx acquisition for $321M; launched Percepta Nasal Swab and Decipher Bladder tests.
- FY 2021 revenue guidance raised to $210-218M from $200-208M, implying 79-86% growth.
- Cash $164M at quarter-end; operating cash used $1.4M incl. $3.9M acquisition expenses.

## SEC filing metadata
- accession: 0001384101-21-000173
- form_type: 8-K
- ticker: VCYT
- cik: 0001384101
- company_name: VERACYTE, INC.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1384101/000138410121000173/0001384101-21-000173-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1384101/000138410121000173/vcyt-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001384101-21-000173
- JSON: https://secwatch.observer/filing/0001384101-21-000173.json
- Plain text: https://secwatch.observer/filing/0001384101-21-000173.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.